Q4 2024 · 13F-HR
Ally Bridge Group (NY) LLCholdings as filed
Filed 2025-02-14 · accession 0000950123-25-002405
$116.6M
Reported value
30
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $12.3M | 10.6% | 147,750 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $9.6M | 8.22% | 173,144 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $7.9M | 6.77% | 114,360 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $5.6M | 4.84% | 66,661 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $5.1M | 4.35% | 129,291 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $5.0M | 4.28% | 174,048 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $4.9M | 4.21% | 116,796 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $4.9M | 4.18% | 55,892 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $4.8M | 4.14% | 90,292 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $4.1M | 3.51% | 244,538 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $3.9M | 3.38% | 87,629 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $3.8M | 3.26% | 1,074,824 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $3.5M | 3.00% | 445,259 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $3.5M | 2.97% | 44,982 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $3.2M | 2.76% | 781,489 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $3.2M | 2.73% | 141,710 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $2.7M | 2.31% | 70,678 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $2.6M | 2.24% | 122,424 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $2.6M | 2.22% | 348,000 | Common | SOLE |
| 00032Q104 | WHWK | AADI BIOSCIENCE INC | $2.6M | 2.21% | 817,939 | Common | SOLE |
| 002120202 | ATYR | ATYR PHARMA INC | $2.5M | 2.17% | 699,730 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $2.5M | 2.13% | 317,833 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $2.4M | 2.09% | 175,063 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $2.3M | 1.99% | 106,434 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $2.3M | 1.97% | 330,275 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $2.2M | 1.90% | 83,176 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $2.0M | 1.69% | 54,692 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $1.7M | 1.42% | 1,576,762 | Common | SOLE |
| 74346M406 | PMNEUR | PROMIS NEUROSCIENCES INC | $1.5M | 1.29% | 1,592,605 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $1.4M | 1.17% | 760,225 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.